Instructions for Nimesil (Nimesulide)
Granules for preparing a suspension for intake in the form of light yellow grain powder with orange smell.
1 pack (2 g)
Nimesulid 100 mg
Auxiliary substances: Macrogol of cetostearyl ether, sugarosis, maltodecstrin, lemon acid of waterless, orange flavor.
Pharmacological groups / Group membership:
NPC. Selective OG-2 inhibitor
List B. Store in a dry, light-protected place inaccessible to children at a temperature not exceeding 25 °C.
Nesteroidal anti-inflammatory drug Nimesulide from the class of sulfonamides. It has an anti-inflammatory, analgesic and heat-reducing effect. Nimesil acts as enzyme inhibitor cyclooxygenase, responsible for the synthesis of prostaglandins, and ingibiates mainly cyclooxenazu-2.
treatment of acute pain (back pain, lower back pain; pain syndrome in the bone and muscle system, including injuries, ligament stretches and joint dislocations, tendenites, bursits; toothache);
symptomatic treatment of osteoarthrosis with pain syndrome;
The drug Nimesulide is designed for symptomatic therapy, pain reduction and inflammation at the time of use.
Method of application, course and dosage:
Nimesulide is taken in, 1 bag (100 mg nemesulid) 2 times/day. The drug Nimesulide is recommended after eating. The contents of the bag fall into a glass and dissolve in about 100 ml of water. The prepared solution is not subject to storage.
Nimesil is used only for patients over 12 years of age.
Teenagers (aged 12-18): On the basis of pharmacokinetic profile and pharmacodynamic characteristics of Nimesil, there is no need to adjust the dose of teenagers.
Patients with disrupted kidney function: On the basis of pharmacokinetic data, there is no need to correct the dose in patients with mild and moderate forms of renal failure (CC 30-80 ml/min).
Older patients: In the treatment of elderly patients, the need to adjust the daily dose is determined by the physician based on the possibility of interaction with other drugs Nimesulide.
The maximum duration of treatment with nemesulid is 15 days.
To reduce the risk of unwanted side effects, a minimum effective dose should be used at a minimum rate.
Joint use with glucocorticosteroids increases the risk of gastrointestinal ulcer or bleeding.
When used in conjunction with anti-rombocitis and selective serotonin reabsorption inhibitors (SSRIs), for example, fluoxetine increases the risk of gastrointestinal bleeding.
NPAs can enhance the action of anticoagulants such as warfarin. Due to the increased risk of bleeding, this combination is not recommended and is contraindicated to patients with severe coagulation disorders. If combined therapy is not avoidable, it is necessary to closely monitor blood congestion.
NPAs can weaken diuretics.
In healthy volunteers, nemesulid temporarily reduces sodium withdrawal by the action of a vyrosemide, to a lesser extent - potassium removal, and reduces the diuretic effect itself.
The combined treatment of Nimesil and vyrosemide results in a reduction (approximately 20%) of the area under the concentration-time curve (AUC) and a reduction in cumulative excretion of the vyrosemide without changing the kidney clearance of the furomeside.
The joint use of vorosemide and nemesulid requires caution in patients with kidney and heart impairment.
APF inhibitors and antagonists of angiotensin receptors II:
NPAs can reduce the effects of antihypertensive drugs. Patients with mild and moderate kidney failure (CC 30-80 ml/min) with joint assignment of APF inhibitors, angiotenzine II antagonists or cycloxygenase suppressors (HCP) OP, anti-aggregators), further deterioration of kidney function and acute renal failure, which is usually reversible. These interactions should be taken into account in patients taking Nimesil in combination with PAP inhibitors or antagonists of angiotensin II receptors. Therefore, the joint use of these drugs Nimesulide is